Diabetic Nephropathy

Background

Diabetic nephropathy (DN), also known as diabetic kidney disease (DKD), represents a frequent and serious microvascular complication of diabetes mellitus. ^[1] It is characterized by progressive kidney damage that can lead to end-stage renal disease (ESRD). ^[1] Approximately 20%–40% of patients with type 2 diabetes (T2D) will develop DKD, with some studies indicating a prevalence of 30–50%. ^[1] Many of these individuals will experience a relentless decline in glomerular filtration rate (GFR), eventually progressing to ESRD. ^[1] The rising prevalence of DN is a significant public health concern, contributing substantially to the global burden of ESRD; for example, in Taiwan, it is the primary cause of increased ESRD incidence and prevalence, making Taiwan one of the countries with the highest rates worldwide. ^[1]

Biological Basis

The development of diabetic nephropathy is complex and influenced by a combination of metabolic, hemodynamic, and genetic factors. ^[1] While risk factors such as age, duration of diabetes, albuminuria grade, and early GFR decline have been identified ^[1] there is substantial evidence for a significant genetic contribution. ^[2] DKD tends to aggregate in families and shows considerable variation in prevalence across different ethnic groups, suggesting underlying genetic predispositions. ^[2]

Identifying specific genetic variants that influence DKD susceptibility is crucial for understanding its biological mechanisms. ^[2] Genome-wide association studies (GWAS) and candidate gene approaches have revealed associations between DN and genes such as TCF7L2, ACE, and SHROOM3. ^[1] However, the exact genetic mechanisms remain largely unclear, and many reported genetic associations have not been consistently replicated, partly due to relatively small sample sizes in some studies. ^[1]

Diabetic nephropathy often co-occurs with other microvascular complications, particularly diabetic retinopathy (DR), with a high concordance rate. ^[1] This observation suggests that DN and DR may share common pathogenic pathways, including glucose metabolism dysregulation, angiogenesis, inflammation, and oxidative stress. ^[1] Consequently, genetic loci with pleiotropic effects, influencing multiple phenotypes, could explain the observed association between DR and DKD. ^[1] Genes implicated in these pathways include IL-10 polymorphisms ^[3] SLC2A1 tag SNPs ^[4] and NADPH Oxidase 4 (NOX4), which is involved in oxidative stress and has been linked to severe diabetic retinopathy and plays a role in renal pathology. ^[5] Other specific genetic variants and loci, such as a SNP on chromosome 9p21 ^[6] variants near ATM ^[7] CPVL/CHN2 ^[8] FTO ^[9] GREM1 ^[10] and SORBS1 ^[11] have also been investigated for their roles in susceptibility to DN. Furthermore, specific SNPs such as rs7583877 in the AFF3 locus, rs17709344 in the RGMA-MCTP2 locus, rs4972593 in the Sp3-CDCA7 locus, rs1801239 in the CUBN locus, and rs161740 in the EPO locus have been examined for their association with diabetic nephropathy. ^[9]

Clinical Relevance

Diabetic nephropathy is a leading cause of chronic kidney disease and progression to ESRD, necessitating renal replacement therapies like dialysis or transplantation. ^[1] The identification of early signs, such as microalbuminuria, is critical for timely intervention. Diabetic retinopathy can serve as a vital clinical biomarker for the diagnosis of DKD, especially in patients with diabetes and microalbuminuria. ^[1] Understanding the genetic underpinnings of DN may lead to improved risk stratification, earlier diagnosis, and the development of targeted therapies. While some individuals with diabetes experience a rapid decline in renal function, others maintain normal kidney function for decades despite suboptimal glycemic control, highlighting the need to better characterize factors, including genetic ones, that influence these variable outcomes. ^[2]

The significant prevalence and serious consequences of diabetic nephropathy impose a substantial burden on individuals and healthcare systems worldwide. ^[1] As a major cause of ESRD, DN contributes to increased morbidity, mortality, and healthcare costs associated with dialysis and kidney transplantation. ^[1] Research into the genetic architecture of DN aims to advance personalized medicine by identifying individuals at higher risk, enabling proactive interventions, and ultimately reducing the societal impact of this devastating complication of diabetes.

Methodological and Statistical Power Limitations

Many studies acknowledge insufficient statistical power due to limited sample sizes, especially for detecting rare genetic variants or those with small effect sizes. ^[12] For instance, some discovery genome-wide association studies (GWAS) had 100% power to detect variants with a genotypic relative risk of 1.5 but only 5% power for a relative risk of 1.2, highlighting the challenge in identifying modest genetic effects. ^[12] This limitation is further compounded by imbalances in case-control sample sizes in some analyses, which can adversely affect association analysis and the ability to identify genetic loci. ^[13]

The chosen study designs, such as multi-stage strategies rather than comprehensive meta-analyses, have been noted as a limitation, potentially reducing overall power and the ability to identify robust associations. ^[11] Furthermore, heterogeneity between discovery and replication cohorts, including differences in diabetes type (Type 1 vs. Type 2 diabetes) or diverse patterns of allelic heterogeneity and linkage disequilibrium across populations, often contributes to a lack of replication for genetic signals. ^[12] This makes it difficult to conclusively validate candidate susceptibility genes like SORBS1 and pinpoint disease-associated functional variants. ^[11]

Phenotypic Heterogeneity and Ascertainment Challenges

A significant limitation arises from the diverse definitions of diabetic nephropathy, which can lead to phenotypic heterogeneity and potential misclassification bias. ^[11] For example, defining diabetic nephropathy solely by the presence of proteinuria, without considering renal function, may overlook distinct genetic predispositions to renal failure versus proteinuria. ^[11] Similarly, the inability to distinguish between Type 1 and Type 2 diabetes, or to adjust for diabetes duration in some analyses, introduces further heterogeneity that can mask true genetic associations. ^[14]

The gold standard for identifying diabetic kidney disease, such as kidney biopsy, is often not feasible in large-scale epidemiological studies, necessitating reliance on clinical criteria that may not fully capture the disease's complexity. ^[14] This can lead to controls who may later develop the disease or cases that inadvertently include individuals with non-diabetic chronic kidney disease, reducing statistical power and potentially biasing results towards the null. ^[12] Moreover, reduced kidney function (estimated glomerular filtration rate, eGFR) and albuminuria are known to develop independently, suggesting distinct underlying mechanisms and genetic effects, making a combined phenotype challenging for genetic studies. ^[2]

Population Diversity and Confounding Factors

Genetic associations identified predominantly in one ancestral group may not be directly transferable or play a significant role in the development of the condition in other populations, thereby limiting the generalizability of findings. ^[15] Studies involving multi-ethnic cohorts face challenges in harmonizing phenotypes across diverse groups and may have reduced power for ancestry-stratified analyses. ^[12] This highlights the ongoing need for broader representation in genetic studies to understand the full spectrum of genetic risk across human populations.

The genetic risk for diabetic nephropathy may constitute only a small proportion compared to the substantial influence of non-genetic risk factors. ^[12] Unaccounted non-genetic or environmental confounders can introduce heterogeneity and lead to inconsistent results across studies. ^[9] Furthermore, the inherent complexity of chronic kidney disease in diabetes, where a significant portion may not be attributable to classic diabetic nephropathy, suggests that other, unmeasured factors or alternative pathologies are at play, contributing to remaining knowledge gaps in disease etiology. ^[2]

Variants

Genetic variations play a crucial role in an individual's susceptibility to complex diseases such as diabetic nephropathy (DN), a severe complication of diabetes that can lead to end-stage kidney disease. Understanding these variants helps to unravel the underlying biological mechanisms contributing to disease progression and identify potential therapeutic targets. Research into genetic predispositions for diabetic kidney disease has identified various loci across the genome, highlighting the polygenic nature of this condition ^[16] These studies underscore the diverse biological pathways that can influence kidney health in the context of diabetes.

Among the identified genetic markers, rs2237896 in the KCNQ1 gene is of interest. The KCNQ1 gene encodes a voltage-gated potassium channel subunit, which is vital for regulating ion flow across cell membranes, particularly in the heart and pancreas. Variations in KCNQ1 have been linked to glucose homeostasis and type 2 diabetes, suggesting that altered pancreatic beta-cell function or insulin secretion due to this variant could indirectly impact kidney health by exacerbating glycemic control. Similarly, the rs3128852 variant is associated with the OR12D2 and OR5V1 genes. While olfactory receptors like OR5V1 are traditionally known for their role in smell, emerging research indicates their expression and function in non-olfactory tissues, including the kidney, where they might modulate cellular processes or signaling pathways. Notably, intronic variations within OR5V1 have been significantly associated with diabetic kidney disease in various cohorts, suggesting a role in disease pathogenesis ^[17] The presence of such a variant might alter gene expression or splicing, thereby affecting kidney function and increasing susceptibility to DN.

Other variants implicate diverse cellular functions critical for kidney health. The rs116216059 variant in the STAC gene family, which encodes adaptor proteins involved in calcium channel regulation, could influence cellular calcium signaling pathways important for podocyte function and glomerular integrity. Perturbations in these pathways might compromise the kidney's filtration barrier, contributing to the development of DN. Likewise, the rs425827 variant in KRT6B, which codes for keratin 6B, a structural protein, may affect the mechanical resilience and repair capabilities of renal cells. Keratins are essential components of the cytoskeleton, providing structural support to cells, and their dysfunction could lead to increased susceptibility of kidney cells to metabolic stress and damage characteristic of diabetic conditions ^[18] The identification of such varied genetic factors highlights the complex interplay of structural, signaling, and metabolic processes in the progression of diabetic nephropathy.

Further genetic insights come from variants in non-coding and less characterized genes. The rs185299109 variant is found within the region of LINC00470 and AIDAP3, representing long intergenic non-coding RNAs that are increasingly recognized for their roles in gene regulation, chromatin modification, and cellular differentiation. Alterations in these regulatory RNAs due to this variant could lead to dysregulated gene expression patterns critical for kidney homeostasis. Similarly, rs149641852 is associated with SNCAIP and MGC32805, genes that might be involved in protein processing or neuronal signaling, which could have indirect effects on renal function given the kidney's rich innervation and complex cellular interactions. Additionally, rs191449639 linked to MUC7 and AMTN, and rs141560952 associated with DIS3L2 and NRBF2P6, point to potential roles for mucin production, RNA degradation, and cellular metabolism in diabetic nephropathy, respectively. The rs115061173 variant in the LINC01266 - RN7SL120P region and rs1000423 in ATP8A1-DT - RN7SKP82 further underscore the involvement of non-coding RNA pathways and membrane transport mechanisms. These variants collectively suggest that a wide array of genetic predispositions, affecting diverse biological processes, contribute to the susceptibility and progression of diabetic kidney disease ^[9]

Key Variants

RS ID	Gene	Related Traits
rs2237896	KCNQ1	HbA1c measurement type 2 diabetes mellitus mosaic loss of chromosome Y measurement glucose tolerance test glucose measurement
rs3128852	OR12D2, OR5V1	diabetic nephropathy
rs116216059	STAC	stage 5 chronic kidney disease diabetic nephropathy
rs185299109	LINC00470 - AIDAP3	glomerular filtration rate diabetic nephropathy
rs149641852	SNCAIP, MGC32805	diabetic nephropathy
rs191449639	MUC7 - AMTN	albuminuria, stage 5 chronic kidney disease diabetic nephropathy
rs141560952	DIS3L2, NRBF2P6	diabetic nephropathy
rs425827	KRT6B	diabetic nephropathy
rs115061173	LINC01266 - RN7SL120P	stage 5 chronic kidney disease diabetic nephropathy
rs10004231	ATP8A1-DT - RN7SKP82	diabetic nephropathy

Defining Diabetic Kidney Disease and its Manifestations

Diabetic kidney disease (DKD), often referred to as diabetic nephropathy (DN), represents a significant microvascular complication arising from both type 1 and type 2 diabetes mellitus. ^[1] It is characterized by progressive kidney damage that can lead to a decline in renal function and, ultimately, kidney failure. The underlying mechanisms of DKD are complex, involving various pathways that contribute to its heterogeneous presentation. ^[19] Research indicates a familial clustering and predisposition to DKD, suggesting genetic susceptibility plays a role in its development. ^[20]

Conceptually, DKD is distinguished from general chronic kidney disease (CKD) by its specific etiology rooted in diabetes. While CKD broadly refers to any long-standing decrease in kidney function or structure, DKD specifically denotes kidney damage caused by diabetes. ^[21] Key features include changes in glomerular barrier function and reduced kidney function, which can be assessed through various diagnostic measures. The progression of DKD is often characterized by stages of renal disease, beginning with incipient diabetic nephropathy and advancing through various degrees of kidney impairment. ^[22]

Classification and Staging of Diabetic Nephropathy

The classification of diabetic nephropathy involves staging the disease based on its progression and severity, primarily through indicators of kidney damage and function. A key classification system relies on the level of albuminuria, which is the excretion of albumin in the urine. This allows for the categorization of patients into states of normoalbuminuria, microalbuminuria, and macroalbuminuria, reflecting increasing severity of glomerular damage. ^[18] The most severe stage of kidney failure is End-Stage Renal Disease (ESRD), defined by the need for ongoing dialysis treatment or a kidney transplant. ^[18]

Research and clinical practice also employ broader classifications, such as chronic kidney disease (CKD), which can be defined by an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2 or a spot urine albumin-to-creatinine ratio (ACR) of 30 μg/mg or greater. ^[14] For genetic studies, phenotypes for DKD can be categorized as "CKD" to identify variants contributing to reduced kidney function, or "CKD and DKD" to identify variants contributing to kidney disease regardless of glomerular barrier dysfunction or reduced function. ^[2] A dimensional approach, such as using eGFR as a continuous phenotype, is also utilized to detect genetic variants influencing kidney function that might not be captured by binary classifications. ^[2]

Diagnostic Markers and Measurement Approaches

The diagnosis and monitoring of diabetic kidney disease rely on specific clinical criteria and measurement approaches, primarily focusing on albuminuria and glomerular filtration rate. Microalbuminuria is operationally defined as an albumin excretion rate (AER) between 20,200 and 30,300 mg/24 hours, or an albumin-to-creatinine ratio (ACR) of 2.5–25 mg/mmol for men and 3.5–35 mg/mmol for women in urine collections. ^[18] Macroalbuminuria, indicating more advanced damage, is defined by an AER greater than 200 mg/minute or 300 mg/24 hours, or an ACR exceeding 25 mg/mmol for men and 35 mg/mmol for women. ^[18] These measurements are typically confirmed in at least two out of three consecutive urine collections to ensure accuracy.

Beyond albuminuria, the estimated glomerular filtration rate (eGFR) is a critical measure of kidney function, often calculated using prediction equations based on serum creatinine. ^[23] A decline in eGFR, particularly below 60 mL/min/1.73 m2, is a key diagnostic criterion for CKD and advanced DKD. ^[14] In research settings, specific criteria are established for defining cases, such as patients with overt albuminuria or those undergoing renal replacement therapy, and controls, often individuals with normoalbuminuria and a long duration of diabetes or the presence of diabetic retinopathy. ^[9] Diabetic retinopathy itself can serve as a clinical biomarker for DKD diagnosis in patients with microalbuminuria, given the high concordance rate between these two microvascular complications. ^[1]

Early Clinical Manifestations and Progression

Diabetic nephropathy (DN), also known as diabetic kidney disease (DKD), often begins insidiously, with early stages typically presenting without overt symptoms. ^[1] A key early indicator is microalbuminuria, defined as an elevated spot urine albumin-to-creatinine ratio (UACR) of ≥30 μg/mg, which serves as a vital clinical biomarker for diagnosis among patients with diabetes. ^[1] As the disease progresses, patients exhibit reduced kidney function, objectively measured by a decline in the estimated glomerular filtration rate (eGFR). ^[2] Uncontrolled hypertension and insulin resistance are also common features and determinants in patients with type 2 diabetes, often preceding or co-occurring with microalbuminuria . ^{[19], [24]}

The progression of diabetic nephropathy can lead to severe outcomes, including end-stage renal disease (ESRD), which is characterized by a significant and often rapid decline in renal function. ^[25] Obesity is also identified as a risk factor for kidney disease in both type 1 and type 2 diabetes. ^[26] The duration of diabetes, along with the patient's age and age at diagnosis, significantly influences the risk of developing these microvascular complications. ^[27]

Diagnostic Markers and Assessment Approaches

Diagnosis and monitoring of diabetic nephropathy rely on objective measurement approaches, primarily focusing on kidney function and damage markers. The estimated glomerular filtration rate (eGFR), derived from serum creatinine levels, is a crucial continuous measure used to assess kidney function, with methods like the Modification of Diet in Renal Disease (MDRD) Study Group equation providing more accurate estimations. ^[23] The albumin-to-creatinine ratio (UACR) in a spot urine sample is another standard diagnostic tool, indicating glomerular barrier dysfunction when elevated. ^[1] Beyond these standard measures, specific urine proteome patterns have shown potential in predicting kidney damage, particularly in patients with type 2 diabetes. ^[28]

Genetic assessment plays an increasing role in understanding susceptibility and progression, often utilizing genome-wide association studies (GWAS) to identify variants associated with different phenotypes of kidney disease . ^{[1], [2]} These genetic studies categorize phenotypes such as "CKD" for reduced kidney function, "CKD and DKD" for general kidney disease, and "eGFR" as a continuous measure. ^[2] Specific genes like TCF7L2, ACE, SHROOM3, IL-10, SLC2A1, CPVL/CHN2, NOX4, FTO, Nidogen-1, AFF3, and ERBB4 have been implicated as susceptibility genes or in relation to associated complications. ^[1]

Phenotypic Diversity and Associated Conditions

Diabetic kidney disease is recognized as a complex and heterogeneous condition, exhibiting significant inter-individual variation in presentation and progression. ^[19] Familial clustering of the disease provides strong evidence for a genetic susceptibility to diabetic nephropathy, highlighting a hereditary component to its development. ^[20] The rate of decline in renal function can also vary with age, and the clinical definition of diabetic nephropathy in type 2 diabetes can be challenging due to the heterogeneity of vascular complications and other potential renal diagnoses. ^[29]

A notable clinical correlation is the high concordance rate between diabetic nephropathy and diabetic retinopathy, with studies suggesting shared underlying pathogeneses involving glucose metabolism, angiogenesis, inflammation, and oxidative stress. ^[1] Diabetic retinopathy can serve as a vital clinical biomarker and predictor for the diagnosis of diabetic kidney disease, especially in patients with microalbuminuria, and can even predict incident renal dysfunction . ^{[1], [28]} This phenotypic diversity extends across different populations, with genetic studies exploring susceptibility in groups such as Taiwanese, Greek, African Americans, Pima Indians, Japanese, and various European descents. ^[1]

Causes of Diabetic Nephropathy

Diabetic nephropathy (DN) is a severe microvascular complication of diabetes mellitus, characterized by progressive kidney damage that can lead to end-stage renal disease. Its development is multifactorial, stemming from a complex interplay of genetic predispositions, metabolic dysregulation, environmental influences, and other modifying factors. While hyperglycemia is a prerequisite, it is often insufficient on its own to trigger the condition, highlighting the role of additional causal elements. ^[30]

Genetic Predisposition and Heritability

Genetic factors are critical in the pathogenesis of diabetic nephropathy, evidenced by varying incidence rates across populations and the familial aggregation of end-stage kidney disease associated with diabetes. ^[30] Heritability is also suggested by the nature of diabetic renal histologic changes, estimated glomerular filtration rate, and proteinuria. ^[30] Genome-wide association studies (GWAS) have identified numerous susceptibility loci and candidate genes, including TCF7L2, ACE, and SHROOM3, which have been linked to DN through various genetic approaches. ^[1] Other identified genetic variants include a single nucleotide polymorphism near ATM associated with metformin response, a variant within the FTO gene conferring susceptibility in Japanese patients, and specific loci like rs7583877 in AFF3, rs17709344 in RGMA-MCTP2, rs4972593 in Sp3-CDCA7, rs1801239 in CUBN, and rs161740 in EPO. ^[5]

Further research has pointed to genes such as Nox4, GREM1, SORBS1, and Nidogen-1 as potential contributors to DN development. ^[5] Polymorphisms in the Renin-Angiotensin-Aldosterone System (RAAS) genes and IL-10 have also been implicated, particularly in Asian populations. ^[31] The presence of pleiotropic genetic effects, where a single genetic locus influences multiple phenotypes, may explain the observed association and shared pathogenesis between diabetic retinopathy and diabetic kidney disease. ^[1] However, the genetic mechanisms remain complex and require further investigation, as some studies have shown no individual or cumulative genetic effect of certain retinopathy-related SNPs on nephropathy risk. ^[1]

Metabolic Dysregulation and Associated Comorbidities

While hyperglycemia is a fundamental characteristic of diabetes, it is insufficient on its own to cause diabetic kidney disease, underscoring the importance of other metabolic and systemic factors. ^[30] Insulin resistance plays a significant role, not only in the development of type 2 diabetes but also as a determinant of diabetic kidney disease, often co-occurring with hypertension and microalbuminuria. ^[24] Obesity is another critical comorbidity, shown to be associated with kidney disease in both type 1 and type 2 diabetes. ^[26]

The close relationship between diabetic nephropathy and other microvascular complications, such as diabetic retinopathy, highlights shared pathogenic pathways. These complications frequently occur together, suggesting common underlying mechanisms involving glucose metabolism, angiogenesis, inflammation, and oxidative stress. ^[1] Therefore, the presence of diabetic retinopathy can serve as a vital clinical biomarker for diagnosing diabetic kidney disease among patients with diabetes. ^[1]

Gene-Environment Interactions and Epigenetic Modifiers

The development of diabetic nephropathy is not solely determined by genetics or environment but arises from their intricate interaction. Genetic predispositions can render individuals more susceptible to the damaging effects of environmental triggers, such as chronic hyperglycemia and lifestyle choices. For instance, specific genetic variants may alter an individual's glycemic response to medications like metformin, indirectly influencing disease progression. ^[5]

Emerging evidence points to the role of epigenetic modifications, which involve heritable changes in gene expression without altering the underlying DNA sequence. These modifications, including DNA methylation and histone modifications, can be influenced by early life events and environmental exposures, potentially contributing to disease susceptibility. Research has explored the genetic examination of methyltransferases like SETD7 and SUV39H1/H2 in relation to the risk of diabetes complications, suggesting that epigenetic mechanisms may modulate an individual's risk for diabetic nephropathy. ^[32]

Beyond the initial causes, several factors significantly influence the progression and severity of diabetic nephropathy. The duration of diabetes is a primary determinant, as prolonged exposure to metabolic dysregulation increases the risk of kidney damage. ^[1] A patient's age also plays a crucial role; older age is associated with a natural decline in renal function, which can exacerbate the effects of diabetes on the kidneys. ^[1]

Furthermore, the initial state of kidney function, indicated by early glomerular filtration rate (GFR) and albuminuria grade, acts as a strong predictor for the relentless decline in GFR and progression to end-stage renal disease. ^[1] These factors, while not direct initiating causes, are powerful modifiers that dictate the trajectory of diabetic nephropathy once established, influencing the rate at which kidney function deteriorates.

Biological Background of Diabetic Nephropathy

Diabetic nephropathy (DN), also known as diabetic kidney disease (DKD), is a severe and progressive microvascular complication of diabetes that stands as the leading cause of end-stage renal disease (ESRD) globally . ^{[18], [33]} This condition affects approximately 30% of individuals with long-standing type 1 and type 2 diabetes and significantly increases the risks of cardiovascular disease and mortality. ^[18] While DN typically emerges after about ten years in type 1 diabetes, it can manifest even at the time of diagnosis in type 2 diabetes, underscoring its varied presentation. ^[33]

Pathophysiological Progression and Renal Structural Changes

The development of diabetic nephropathy is a complex process characterized by a sequence of functional and structural changes within the kidneys. Early stages often involve glomerular hyperfiltration, where the kidneys initially overwork, which then progresses to albuminuria—the abnormal excretion of protein into the urine—and a gradual decline in the estimated glomerular filtration rate (eGFR) . ^{[18], [33]} These functional deteriorations are accompanied by distinctive structural alterations, including the thickening of the glomerular basement membrane, as well as the basement membranes of the capillaries and renal tubules. ^[33] These changes compromise the kidney's filtering capacity and contribute to the progressive loss of renal function and eventual ESRD. ^[33]

Molecular and Cellular Drivers of Kidney Damage

The pathogenesis of diabetic nephropathy is rooted in a cascade of molecular and cellular events, driven primarily by prolonged hyperglycemia, though hyperglycemia alone is not sufficient to cause the disease. ^[30] Shared mechanisms with other microvascular complications like diabetic retinopathy include increased oxidative stress, chronic inflammation, and aberrant angiogenesis. ^[1] Key signaling pathways, such as the JAK/STAT pathway, show enhanced expression in human diabetic nephropathy, and inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions suggests its critical role . ^{[34], [35], [36]} Furthermore, the NADPH oxidase (NOX) system, particularly NOX4, contributes to oxidative stress in the diabetic kidney, with therapeutic potential seen in dual Nox1/Nox4 inhibitors . ^{[37], [38]} Cellular processes like autophagy also play a significant role, with studies exploring its regulation and pathological implications in DKD, and interventions like metformin shown to enhance autophagy and alleviate oxidative stress via the AMPK/SIRT1-FoxO1 pathway . ^{[28], [39]}

Genetic Predisposition and Regulatory Mechanisms

Genetic factors are crucial determinants of susceptibility to diabetic nephropathy, as evidenced by the variable incidence rates across populations and the observed clustering of DKD-associated ESRD within families . ^{[30], [33]} Genome-wide association studies (GWAS) have identified multiple loci linked to kidney function and chronic kidney disease, although early findings for DKD were often inconsistent due to limited sample sizes. ^[30] However, more recent meta-analyses have begun to uncover genome-wide significant and replicated signals. ^[30] Specific genes implicated in DN susceptibility include TCF7L2, ACE, SHROOM3, and polymorphisms in the Renin-Angiotensin-Aldosterone system . ^{[1], [31]} Other noteworthy genetic variants include rs7583877 in the AFF3 locus, rs17709344 in RGMA-MCTP2, rs4972593 in Sp3-CDCA7, rs1801239 in CUBN, and rs161740 in EPO. ^[9] The MYH9 gene has been strongly associated with ESRD in African Americans, while a leucine repeat in the CNDP1 gene is linked to diabetic ESRD in European Americans. ^[15] Additionally, genes like Nidogen-1 (NID1), a component of basement membranes, NADPH Oxidase 4 (NOX4), SLC2A1, IL-10, CHD2 (a chromatin remodeling enzyme), SOLUTE CARRIER FAMILY 12 (SODIUM/CHLORIDE) MEMBER 3 (SLC12A3), and FTO have been associated with DN or related phenotypes . ^{[3], [4], [5], [9], [33], [40], [41]} Beyond sequence variations, epigenetic modifications, such as DNA methylation, can sustain an "inflamed" memory in immune cells, exacerbating kidney inflammatory responses. ^[42]

Systemic Connections and Biomarkers

Diabetic nephropathy does not occur in isolation but is often intricately linked with other systemic complications of diabetes. Diabetic retinopathy (DR) and DN are both major microvascular complications that frequently co-occur, suggesting shared underlying pathogeneses involving glucose metabolism, angiogenesis, inflammation, and oxidative stress. ^[1] The presence of DR can serve as a vital clinical biomarker for diagnosing DKD in diabetic patients, and specific urine proteome patterns indicative of eye damage can also predict kidney damage . ^{[1], [28], [43]} Beyond microvascular links, systemic factors such as insulin resistance, hypertension, and obesity are significant determinants of DKD, further highlighting its complex, multi-factorial nature and its broader impact on cardiovascular health . ^{[19], [24], [26]}

Dysregulated Signaling and Transcriptional Networks

Diabetic nephropathy (DN) involves a complex interplay of signaling pathways that become dysregulated under hyperglycemic conditions, driving cellular damage and fibrosis. A key player is the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, which exhibits enhanced expression in human DN and plays a significant role in its pathogenesis. ^[34] Specifically, the JAK2/STAT3 cascade mediates the upregulation of vascular endothelial growth factor (VEGF) in high glucose environments, contributing to microvascular changes. ^[36] Furthermore, the insulin-like growth factor (IGF1)/phosphatidylinositol 3-kinase (PI 3-kinase) signaling pathway is implicated, with SASH1 identified as a downstream target that may contribute to disease progression. ^[1] Transcriptional networks centered around genes like AFF3 and the receptor tyrosine kinase ERBB4 are also suggested to be operational in the pathogenesis of kidney disease in diabetes, highlighting the role of coordinated gene expression changes. ^[18] The Renin-Angiotensin-Aldosterone system (RAAS) also features prominently, with gene polymorphisms within this system linked to type 2 DN. ^[31]

Another critical signaling component is NADPH Oxidase 4 (NOX4), which is associated with severe diabetic retinopathy and plays a role in renal pathology in type 1 diabetes. ^[5] Targeting NOX4 has shown promise in attenuating renal damage, underscoring its involvement in oxidative stress-mediated injury. ^[37] The soluble guanylyl cyclase pathway is also observed in the kidney, though its precise role in DN requires further elucidation. ^[44] These interconnected signaling cascades and transcriptional programs collectively contribute to the pathological changes observed in the kidney during diabetes.

Metabolic Imbalance and Oxidative Stress

Metabolic dysregulation is a central mechanism in the development and progression of diabetic nephropathy, often sharing common pathogenic features with diabetic retinopathy, such as altered glucose metabolism, inflammation, and oxidative stress. ^[1] High glucose levels lead to increased oxidative stress, a critical factor in kidney injury. Therapeutic interventions like metformin have been shown to alleviate oxidative stress and enhance autophagy in DN through activation of the AMPK/SIRT1-FoxO1 pathway. ^[39] Autophagy, a cellular process for degrading and recycling damaged components, is often dysregulated in DN, and its modulation represents a potential therapeutic avenue. ^[28]

The renal handling of glucose is also significantly altered, with the sodium-glucose cotransporter 2 (SGLT2) playing a key role in glucose reabsorption. Knockout of SGLT2 in diabetic models attenuates hyperglycemia and glomerular hyperfiltration, although it does not prevent kidney growth or injury, indicating its involvement in early metabolic adaptations. ^[45] Furthermore, the metabolism of angiotensin II to angiotensin III is an obligatory step for certain zona glomerulosa cell-mediated relaxations, highlighting intricate metabolic conversions within the kidney that can impact renal function. ^[46] These metabolic shifts and the resulting oxidative damage are fundamental drivers of cellular dysfunction and tissue remodeling in DN.

Inflammation and Immune Cell Contributions

Inflammation and the immune system play a significant role in the pathogenesis of diabetic kidney disease, contributing to kidney inflammatory responses. Research suggests that DNA methylation can sustain an "inflamed" memory in peripheral immune cells, which then exacerbates kidney inflammation in chronic kidney disease. ^[42] This indicates a long-lasting epigenetic programming of immune cells that contributes to ongoing renal damage. The adaptive immune system, including specific immune cells, is also recognized for its involvement in DN. ^[28]

Genetic factors related to the immune response, such as human leukocyte antigens (HLA), have associations with renal function and kidney disease, indicating a genetic predisposition to immune-mediated renal complications. ^[47] Inflammatory targets are widely recognized in diabetic nephropathy, underscoring the importance of immune cell-mediated processes in disease progression. ^[1] These immune and inflammatory pathways contribute to the complex network of interactions leading to kidney damage in diabetes.

Genetic and Epigenetic Regulatory Aberrations

Genetic predisposition and epigenetic modifications are crucial regulatory mechanisms influencing susceptibility and progression of diabetic nephropathy. Genome-wide association studies (GWAS) have identified numerous genes associated with DN, including TCF7L2, ACE, and SHROOM3, highlighting a genetic basis for risk. ^[1] Beyond direct genetic variants, epigenetic mechanisms like DNA methylation play a role, as observed in the sustained "inflamed" memory of peripheral immune cells aggravating kidney inflammation. ^[42] Chromatin remodeling, which alters gene accessibility, is also implicated; a mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype, suggesting its regulatory importance. ^[40]

Furthermore, post-transcriptional regulatory mechanisms, such as microRNAs, contribute to disease pathology. For instance, MicroRNA-377 has been consistently upregulated in in vitro and in vivo diabetic nephropathy models, and the ribosomal protein RPS12 is a potential target gene. ^[1] If RPS12 is also upregulated in the diabetic milieu, it could contribute to disease progression. These genetic and epigenetic aberrations collectively modulate gene expression and protein function, driving the molecular changes underlying diabetic nephropathy.

Risk Stratification and Early Detection

Diabetic nephropathy (DN) represents a significant complication of diabetes, and identifying individuals at high risk for its development and progression is crucial for effective patient management. Research indicates a strong familial predisposition to renal disease in diabetic patients, with familial clustering of diabetic kidney disease suggesting underlying genetic susceptibility. ^[20] This genetic component, alongside clinical markers, aids in risk assessment and the implementation of early prevention strategies. For instance, the presence of diabetic retinopathy (DR) is considered a vital clinical biomarker for diagnosing diabetic kidney disease among patients with diabetes and microalbuminuria, indicating shared pathogenic mechanisms between these microvascular complications. ^[1] Furthermore, studies suggest that urine proteome specific for eye damage can also predict kidney damage in patients with type 2 diabetes, offering a potential non-invasive diagnostic utility. ^[28]

Beyond genetic predisposition, clinical factors such as obesity, insulin resistance, and hypertension are closely associated with kidney disease in both type 1 and type 2 diabetes, highlighting the multifactorial nature of DN risk. ^[26] Genetic variants influencing blood pressure and cardiovascular disease risk may also impact DN susceptibility, further emphasizing the complex interplay of genetic and environmental factors in risk stratification. ^[48] Therefore, a comprehensive risk assessment integrating family history, genetic insights, and clinical biomarkers is essential for identifying high-risk individuals and tailoring personalized preventive interventions.

Prognostic Indicators and Disease Monitoring

Monitoring the progression of diabetic nephropathy and predicting long-term outcomes is paramount for guiding treatment decisions and improving patient prognosis. Diabetic retinopathy serves as a significant prognostic indicator, with its presence predicting other diabetic complications, including nephropathy. ^[43] Specifically, retinal vascular geometry has been shown to predict incident renal dysfunction in young individuals with type 1 diabetes, highlighting the utility of ophthalmic examinations in assessing renal risk. ^[49] The rate of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes further underscores the interconnectedness of these microvascular complications and their combined prognostic value. ^[50]

Regular monitoring of renal function, including estimated glomerular filtration rate (eGFR) and albuminuria, is foundational for tracking disease progression. Studies have documented a rapid decline to end-stage renal disease (ESRD) as an often-unrecognized feature of nephropathy in diabetes, emphasizing the need for vigilant surveillance. ^[25] The long-term implications of DN are also influenced by factors such as age, age at diabetes diagnosis, and the duration of diabetes, all of which impact the risk of both microvascular and macrovascular complications and overall mortality. ^[27] Accurate methods to estimate GFR from serum creatinine, such as the Modification of Diet in Renal Disease (MDRD) Study equation, provide more precise measures for monitoring renal decline. ^[23]

Genetic Architecture and Therapeutic Targets

The identification of genetic variants associated with diabetic nephropathy offers crucial insights into its pathogenesis and paves the way for personalized medicine approaches and novel therapeutic strategies. Genome-wide association studies (GWAS) and meta-analyses have identified numerous genes, including TCF7L2, ACE, and SHROOM3, as associated with DN susceptibility. ^[1] These studies have uncovered novel susceptibility loci across diverse populations, including African Americans, Korean cohorts, and individuals with type 2 diabetes, broadening the understanding of DN's genetic landscape. ^[15] For instance, a variant within the FTO gene has been found to confer susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. ^[9]

Further research has elucidated the involvement of specific signaling pathways, such as the JAK/STAT pathway, in diabetic nephropathy, with evidence suggesting that inhibition of JAK2/STAT3-mediated VEGF upregulation can mitigate renal damage. ^[35] Additionally, the NADPH Oxidase 4 (NOX4) gene has been implicated in severe diabetic retinopathy and plays a role in diabetic nephropathy, suggesting potential therapeutic targets for reducing oxidative stress and inflammation in the kidney. ^[5] Understanding these genetic associations and biological pathways is critical for developing targeted therapies and implementing personalized medicine approaches that consider an individual's genetic profile to optimize treatment selection and improve outcomes in patients with diabetic nephropathy. ^[51]

Frequently Asked Questions About Diabetic Nephropathy

These questions address the most important and specific aspects of diabetic nephropathy based on current genetic research.

1. My parents have kidney problems from diabetes. Will I get it too?

It's more likely, yes. Diabetic kidney disease tends to run in families, suggesting a strong genetic predisposition. This means if your close relatives have it, you might have inherited some of the genetic factors that increase your own risk.

2. I'm from [ethnic background]. Does that change my kidney risk with diabetes?

Yes, your ethnic background can influence your risk. Studies show that the prevalence of diabetic kidney disease varies significantly across different ethnic groups, indicating that underlying genetic predispositions differ among populations.

3. My friend has diabetes but their kidneys are fine. Why are mine getting worse?

This difference often comes down to individual genetic factors. Some people with diabetes are more genetically susceptible to kidney damage, even with similar blood sugar control, while others are more protected. Genetics play a significant role in these variable outcomes.

4. I have eye problems from diabetes. Does that mean my kidneys are also at risk?

Yes, there's a strong connection. Diabetic kidney disease often occurs alongside diabetic retinopathy (eye damage), with a high concordance rate. This suggests they share common underlying biological pathways and potentially some of the same genetic risk factors.

5. I manage my diabetes well. Can my genes still make my kidneys worse?

Yes, even with diligent management, your genetic makeup can still influence your kidney health. While good control is crucial, genetic factors contribute significantly to how susceptible your kidneys are to damage, explaining why some people progress faster than others despite similar care.

6. Is there a way to know my kidney risk early, before serious damage occurs?

Absolutely. Early signs like microalbuminuria (small amounts of protein in your urine) are critical to identify. Additionally, having diabetic retinopathy can be a key clinical indicator for kidney disease, and future genetic tests may help stratify your risk even earlier.

7. Could a special test tell me if I'm at high risk for kidney damage from diabetes?

Research is actively working on this. Identifying specific genetic variants that influence kidney disease susceptibility is crucial for personalized medicine. In the future, genetic tests could help pinpoint individuals at higher risk, allowing for more proactive interventions.

8. Why do some people with diabetes get kidney disease, but others don't, even with similar blood sugar levels?

This difference is largely due to genetic factors. While high blood sugar is a trigger, your individual genetic makeup determines how your kidneys respond to that stress. Some people have genetic variations that make their kidneys more vulnerable, while others are more resilient.

9. I've heard some people are just 'wired' differently when it comes to kidney health. Is that true?

Yes, it is true. Your genetic "wiring" influences your susceptibility. Specific genetic variations in genes like ACE, NOX4, or FTO have been linked to an increased risk of diabetic kidney disease, affecting how your body responds to diabetes.

10. If I'm at high risk due to my family, what can I do differently to protect my kidneys?

Knowing you're at high risk can empower you to be more proactive. This means extra vigilance with blood sugar control, regular kidney screenings, and discussing personalized strategies with your doctor. Future genetic insights may even lead to targeted preventative therapies.

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Hsieh AR, et al. Lack of association of genetic variants for diabetic retinopathy in Taiwanese patients with diabetic nephropathy. BMJ Open Diabetes Res Care. 2019;8.

[2] van Zuydam NR, et al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes. 2018;67.

[3] Shu Y, Chen Y, Luo H, et al. The roles of IL-10 gene polymorphisms in diabetes mellitus and their associated complications: a meta-analysis. Horm Metab Res. 2018;50:811–5.

[4] Siokas V, Fotiadou A, Dardiotis E, et al. SLC2A1 tag SNPs in Greek patients with diabetic retinopathy and nephropathy. Ophthalmic Res. 2019;61:26–35.

[5] Meng, W., et al. "A genome-wide association study suggests new evidence for an association of the NADPH Oxidase 4 (NOX4) gene with severe diabetic retinopathy in type 2 diabetes." Acta Ophthalmol, 2017.

[6] Fagerholm, E., et al. "SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes." Diabetologia, vol. 55, 2012, pp. 2386–2393.

[7] GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K, et al. "Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes." Nature Genetics, vol. 43, 2011, pp. 117–120.

[8] Hu C, Zhang R, Yu W, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes. 2011;60:3085–9.

[9] Taira M, et al. A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. PLoS One. 2018;13(12):e0208654.

[10] McKnight, A. J., et al. "A GREM1 gene variant associates with diabetic nephropathy." Journal of the American Society of Nephrology, vol. 21, 2010, pp. 773–781.

[11] Germain, M. "SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes." Diabetologia, 2015.

[12] Pollack, S. "Multiethnic Genome-wide Association Study of Diabetic Retinopathy using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control." Diabetes, 2019.

[13] Imamura, M. "Genome-Wide Association Studies Identify Two Novel Loci Conferring Susceptibility to Diabetic Retinopathy in Japanese Patients with Type 2 Diabetes." Human Molecular Genetics, 2021.

[14] Pan, Y. "Whole-Exome Sequencing Study Identifies Four Novel Gene Loci Associated with Diabetic Kidney Disease." Human Molecular Genetics, 2022.

[15] McDonough CW, et al. A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int. 2011;79(9):1004-1013.

[16] Guan, M. "Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans." Human Genomics, 2019.

[17] Jin H, et al. Identification of genetic variants associated with diabetic kidney disease in multiple Korean cohorts via a genome-wide association study mega-analysis. BMC Med. 2023;21(1):15.

[18] Sandholm N, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet. 2012;8(10): e1002921.

[19] Karalliedde J, Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant. 2016;31:206–213.

[20] Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320(18):1161–5.

[21] Alicic, R. Z., Rooney, M. T., and Tuttle, K. R. "Diabetic kidney disease." Clinical Journal of the American Society of Nephrology, vol. 12, 2017, pp. 2032–45.

[22] Mogensen, C. E., Christensen, C. K., and Vittinghus, E. "The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy." Diabetes, vol. 32, 1983, pp. 64–78.

[23] Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease Study Group. Ann Intern Med. 1999;130:461–70.

[24] Groop L, Ekstrand A, Forsblom C, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:642–647.

[25] Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91(6):1300–11.

[26] Hill CJ, Cardwell CR, Maxwell AP, et al. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit. QJM. 2013;106:933–44.

[27] Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57(12):2465–74.

[28] Yang J-K, Wang Y-Y, Liu C, et al. Urine proteome specific for eye damage can predict kidney damage in patients with type 2 diabetes: a case-control and a 5.3-Year prospective cohort study. Diabetes Care. 2017;40:253–60.

[29] Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–85.

[30] Iyengar, S. K. "Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND)." PLoS Genetics, 2015.

[31] Ahmad, N. et al. "Renin–Angiotensin–Aldosterone system gene polymorphisms and type 2 diabetic nephropathy in Asian populations: an updated meta-analysis." Curr Diabetes Rev, vol. 15, 2019, pp. 263–76.

[32] Syreeni, A., El Osta, A., Forsblom, C., et al. "Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes." Diabetes, vol. 60, 2011, pp. 3073–3080.

[33] Khattab A, Torkamani A. Nidogen-1 could play a role in diabetic kidney disease development in type 2 diabetes: a genome-wide association meta-analysis. Hum Genomics. 2022;16:47.

[34] Berthier, C. C. et al. "Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy." Diabetes, vol. 58, 2009, pp. 469–477.

[35] Marrero, M. B. et al. "Role of the JAK/STAT signaling pathway in diabetic nephropathy." Am J Physiol Renal Physiol, vol. 290, 2006, pp. F762–8.

[36] Zheng, Z. et al. "Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through." Journal of Biological Chemistry, vol. 284, no. 48, 2009, pp. 33336-33344.

[37] Gorin, Y. and K. Block. "Nox4 and diabetic nephropathy: witha friendlikethis whoneeds enemies?" Free Radic Biol Med, vol. 61, 2013, pp. 130–142.

[38] Gorin, Y. et al. "Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes." Am J Physiol Renal Physiol, vol. 308, 2015, pp. F1276–F1287.

[39] Ren, H. et al. "Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway." Mol Cell Endocrinol, vol. 500, 2020, p. 110628.

[40] Marfella, C. G. et al. "A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype." Kidney Blood Press Res, vol. 31, 2008, pp. 421–432.

[41] Tanaka, N. et al. "Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms." Diabetes, vol. 52, 2003, pp. 2848–53.

[42] Chen, X. J. et al. "DNA methylation sustains “inflamed” memory of peripheral immune cells aggravating kidney inflammatory response in chronic kidney disease." Front Physiol, vol. 12, 2021, p. 637480.

[43] El-Asrar AMA, Al-Rubeaan KA, Al-Amro SA, et al. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol. 2001;24:1–11.

[44] Theilig, F. et al. "Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver." J Am Soc Nephrol, vol. 12, 2001, pp. 2209–20.

[45] Vallon, V. et al. "Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus." Am J Physiol Renal Physiol, vol. 304, no. 2, 2013, pp. F156–67.

[46] Kopf, P. G., et al. "Obligatory metabolism of angiotensin II to angiotensin III for zona glomerulosa cell-mediated relaxations." Am J Physiol Renal Physiol, vol. 315, no. 4, 2018, pp. F1029-F1039.

[47] Lowe, M., et al. "Associations between human leukocyte antigens and renal function." Sci Rep, vol. 11, no. 1, 2021, p. 3158.

[48] Ehret, G. B., Munroe, P. B., Rice, K. M., et al. "Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk." Nature, vol. 478, 2011, pp. 103–109.

[49] Benitez-Aguirre PZ, Sasongko MB, Craig ME, et al. Retinal vascular geometry predicts incident renal dysfunction in young people with type 1 diabetes. Diabetes Care. 2012;35:599–604.

[50] Penno G, Solini A, Zoppini G, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35:2317–23.

[51] Paternoster, L., Tilling, K., Davey Smith, G. "Genetic epidemiology and Mendelian randomization for informing disease therapeutics: conceptual and methodological challenges." PLoS Genet, vol. 10, 2014, p. e1004234.